Modified B Cells and Methods of Use Thereof - EP4203978A1
Summary
The European Patent Office published patent application EP4203978A1 for Modified B Cells and Methods of Use Thereof, filed by Walking Fish Therapeutics, Inc. The patent covers engineered B cells for therapeutic applications, including cancer treatment indications (A61P 35/00). The application contains 18 IPC classifications spanning peptides, immunology, gene therapy vectors, and therapeutic preparations.
What changed
EPO published patent application EP4203978A1 for modified B cells and methods of use, filed by Walking Fish Therapeutics, Inc. The patent application covers engineered B cells for therapeutic applications including immune cell engineering and cancer treatment. The application lists 18 IPC classifications including C07K (peptides), C12N (microorganisms/enzymes), A61K (medicinal preparations), and C07K 16/28 and C07K 16/30 (antibodies), with designated states covering all major European Patent Convention member states.
For biotechnology and pharmaceutical companies, this patent publication establishes intellectual property protection for modified B cell therapies in the European market. Companies developing CAR-T or similar B cell-based immunotherapies should review the scope of this patent for freedom-to-operate considerations. The A61P 35/00 classification indicates potential oncology applications, expanding the therapeutic reach of this intellectual property.
Archived snapshot
Apr 17, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
MODIFIED B CELLS AND METHODS OF USE THEREOF
Publication EP4203978A1 Kind: A1 Apr 08, 2026
Applicants
Walking Fish Therapeutics, Inc.
Inventors
BOYLE, Kathleen, PARK, Hangil, KOTHAKOTA, Srinivas, SELBY, Mark, BRENNAN, Thomas, WILLIAMS, Lewis T.
IPC Classifications
A61K 40/13 20250101AFI20250417BHEP A61K 40/24 20250101ALI20250417BHEP A61K 40/31 20250101ALI20250417BHEP A61K 40/42 20250101ALI20250417BHEP A61K 39/00 20060101ALI20250417BHEP C12N 15/85 20060101ALI20250417BHEP A61K 35/17 20150101ALI20250417BHEP C07K 16/28 20060101ALI20250417BHEP C12N 15/87 20060101ALI20250417BHEP C07K 14/705 20060101ALI20250417BHEP C12N 5/0781 20100101ALI20250417BHEP A61P 35/00 20060101ALI20250417BHEP C07K 14/495 20060101ALI20250417BHEP C07K 14/54 20060101ALI20250417BHEP C07K 14/725 20060101ALI20250417BHEP C07K 14/71 20060101ALI20250417BHEP C07K 14/715 20060101ALI20250417BHEP C07K 16/30 20060101ALI20250417BHEP C12N 15/117 20100101ALI20250417BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for EPO Patent Bulletin - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.